DOCSLIB.ORG

Better Global Tools for Influenza

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Better Global Tools for Influenza 11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment Prevent. Control. Prepare. 11–12 June 2019 | Geneva, Switzerland BETTER GLOBAL TOOLS FOR INFLUENZA Technical consultation on product research & innovation for influenza prevention, control & treatment WHO/WHE/IHM/IPR/2019.1 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Better global tools for influenza. Technical consultation on product research and innovation for influenza prevention, control and treatment, Geneva, Switzerland, 11-12 June 2019. Geneva: World Health Organization; 2019 (WHO/WHE/IHM/IPR/2019.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use. This publication contains the report of the June 2019 Technical Consultation on Product Research and Innovation for Influenza Prevention, Control and Treatment and does not necessarily represent the decisions or policies of WHO. Written by Sian Lewis Design & layout by Vivian Lee CONTENTS Executive summary 4 PART I Introduction 5 Setting the scene WHO framework 6 PART II Innovating for influenza 7 The role of innovation Understanding virus characteristics and host factors 9 Building on lessons learnt 10 PART III Landscape overview 12 Towards better tools Diagnostics 13 Vaccines 14 Therapeutics 17 PART IV Scenario planning 21 Action planning Recommendations for action 22 Next steps 25 Annex I: Meeting agenda 26 Annex II: List of participants 28 Annex III: Individual suggestions 32 NOTE TO READER This report aims to capture key messages that emerged from the presentations and discussions rather than trying to provide a strictly chronological account of the meeting. The priorities for innovation and recommendations for action include suggestions made by all meeting participants (across all sessions), and do not necessarily imply consensus. Some priorities for innovation are repeated to reflect their emphasis by participants in different sessions and contexts. The presentations and background reading for the meeting are available at: https://www.who.int/influenza/global_influenza_ strategy_2019_2030/en/. Technical consultation on product research and innovation for influenza prevention, control and treatment | BETTER GLOBAL TOOLS FOR INFLUENZA | 1 ACRONYMS AND ABBREVIATIONS AMR antimicrobial resistance BARDA Biomedical Advanced Research and Development Authority CDC Centers for Disease Control CVV candidate vaccine virus DIA digital immunoassay FAO Food and Agriculture Organization of the United Nations FDA Food and Drug Administration GAP Global Action Plan for Influenza Vaccines GISRS Global Influenza Surveillance and Response System HA hemagglutinin HICs high-income countries IHR International Health Regulations (2005) LAIV live attenuated influenza vaccine LMICs low- and middle-income countries mAbs monoclonal antibodies NAAT nucleic acid amplification test NAI neuraminidase inhibitor NPI nonpharmaceutical intervention PAI polymerase inhibitor PCR polymerase chain reaction PIP Pandemic Influenza Preparedness R&D research and development RIDT rapid influenza diagnostic test RCT randomized control trial SDG Sustainable Development Goal WHE WHO Health Emergencies Programme WHO World Health Organization 2 | BETTER GLOBAL TOOLS FOR INFLUENZA | Technical consultation on product research and innovation for influenza prevention, control and treatment EXECUTIVE SUMMARY The 2019–2030 Global Influenza Strategy aims to protect all people Table 1. Sumtmary recommendations for delivering better global tools and communities from the threat of influenza by delivering better global to tackle influenza tools and stronger country capacities for tackling the virus and disease. Boost public understanding, confidence & uptake As a first step towards implementing the strategy, WHO convened • Find new ways to engage & inform the public a meeting of experts in June 2019 to explore the challenges and • Target messaging to key groups opportunities in research and innovation for developing new and improved products to prevent, treat, and potentially control influenza. Build political will • Turn global strategy into call for action • Make an effective case for investment Meeting participants reviewed the latest trends and current product • Leverage burden of disease studies pipelines in diagnostics, vaccines, and therapeutics. For each type of product, they identified knowledge gaps and barriers to development Secure funds and direct investors and utilization and put forward a selection of priorities for innovation. • Fundraise beyond the private sector These ranged from broad goals, for example to improve the way we • Coordinate donors • Direct investors towards high impact action collect and share data, to very specific suggestions such as conducting fixed and focused studies to better understand influenza transmission Work together to align efforts patterns in hospitals. • Build partnerships across research & clinical practice • Improve infrastructure for alignment & Key recommendations are highlighted throughout this report and collaboration summarized in Table 1. A common theme across product types was the • Harness new applications & methods for data need to focus on making tools as relevant and effective as possible. sharing This is not necessarily about only creating new tools or technologies, • Adopt a holistic view of production although participants agreed that developing a universal vaccine Strengthen the evidence base would be a significant leap forward. Rather, it is also about improving • Improve understanding of the virus and increasing the utilization of the currently available products and • Leverage existing or establish new clinical technologies through incremental innovations. networks • Harness existing evidence • Harmonize clinical trial methods Several speakers suggested that small technological innovations could make a big difference to efficiency and effectiveness, for example Support early detection & rapid data sharing by expanding breadth of protection for seasonal influenza vaccines. • Develop deployable diagnostics Incorporating public health outcomes in clinical trials or redesigning • Strengthen global surveillance clinical trials to focus on public health outcomes would help make Improve vaccine production efficiencies influenza products more relevant to health ministers and key decision • Speed up vaccine production makers. And tailoring existing diagnostics, vaccines, and therapeutics to • Streamline manufacturing processes resource-limited contexts would make them more appealing,
Load more

Recommended publications
  • COVID-19 Infection Prevention Control Strategies For
    COVID-19 Infection Prevention Control Strategies for Massachusetts Masonic Facilities DRAFT 4/6/2020 Introduction With phrases such as “social distancing,” “self-quarantine,” and “flattening the curve” still showing up in the media, flattening the curve” still showing up in the media, blood donations have plummeted as schools, offices and other sites that typically host blood drives shut down to prevent the spread of coronavirus. As Masonic lodges across the commonwealth rise to meet the growing demand for locations, all masons must understand and be able to effectively communicate to others the importance of precautionary measures against the potential spread of CODID-19 while hosting blood drives in our buildings. Background The COVID-19 virus has actually been named "SARS-CoV-2," and the disease it causes has been named "coronavirus disease 2019" (abbreviated "COVID-19"). The virus looks like it's wearing a spiky crown, so it gets the name "corona" from the Latin word for crown. The virus enters cells using the "spike" on its surface to enter and bond with a human cell. Once inside human cells, the virus reproduces. Those reproductions break out of cells and infect other human cells. At a certain point, there are so many virus particles being produced that our normal cells can't work properly and we get sick. Viruses are believed to be transmitted from person-to-person primarily through virus-laden droplets that are generated when infected persons speak, cough, or sneeze. These droplets can be deposited onto the mucosal surfaces of susceptible persons or hard surfaces that are within 6 feet of the droplet sourcei.
    [Show full text]
  • Prevention and Control of Influenza During a Pandemic for All Healthcare Settings
    Annex F Prevention and Control of Influenza during a Pandemic for All Healthcare Settings Date of Latest Version: May 2011 1. E-Links have been inserted to direct the reader to the appropriate Section of the Annex. 2. This Annex has been developed for use by healthcare workers including but not limited to those working in infectious diseases, risk management, infection prevention and control, occupational health, occupational hygiene and/or emergency response. 3. The recommendations in this Annex must be interpreted by trained personnel prior to implementation in specific situations, organizations or healthcare settings. 4. A major assumption underlying this Annex was that a pandemic virus would cause severe disease in patients. - Should mild disease occur as in pH1N1, recommendations related to PPE may change. 5. As with all guidance documents related to pandemic influenza, healthcare organizations and personnel should be mindful of specifc provincial/ territorial legislation and policies that may influence or supersede the application of some of the recommendations in this Annex. 6. NOTE: This version of Annex F is being published after the pH1N1 Pandemic (H1N1). The assumptions about influenza epidemiology in this document are generalized to include all potential influenza pandemics and are not specific to pH1N1. To view the PHAC Guidance Documents related to pH1N1 go to: http:///www.phac-aspc.gc.ca/alert-alerte/h1n1/ guidance_lignesdirectrices-eng.php. These Guidance Documents have been adapted from this Annex based on emerging epidemiologic evidence and the impact of pH1N1 infection. 7. In Canada, public health is a shared responsibility of the Federal, Provincial and Territorial governments.
    [Show full text]
  • Strategies for Improving Influenza Immunization Rates Among Hard-To-Reach Populations
    Journal of Urban Health: Bulletin of the New York Academy of Medicine, Vol. 84, No. 4 doi:10.1007/s11524-007-9197-z * 2007 The New York Academy of Medicine For permissions, please e-mail: [email protected] Advance Access publication Strategies for Improving Influenza Immunization Rates among Hard-to-Reach Populations David Vlahov, Micaela H. Coady, Danielle C. Ompad, and Sandro Galea ABSTRACT Whereas considerable attention has been devoted to achieving high levels of influenza immunization, the importance of this issue is magnified by concern over pandemic influenza. Most recommendations for vaccine administration address high risk groups such as the elderly and those with chronic diseases, but coverage for hard- to-reach (HTR) populations has had less attention. HTR populations include minorities but also include other primarily urban groups such as undocumented immigrants, substance users, the homeless, and homebound elderly. Obstacles to the provision of immunization to HTR populations are present at the patient, provider, and structural levels. Strategies at the individual level for increasing immunization coverage include community-based educational campaigns to improve attitudes and increase motivation for receiving vaccine; at the provider level, education of providers to encourage immunizations, improving patient–provider interactions, broadening the provider base to include additional nurses and pharmacists, and adoption of standing orders for immunization administration; and at the structural level, promoting
    [Show full text]
  • HHS 2009 H1N1 Influenza Improvement Plan
    U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 2009 H1N1 Influenza Improvement Plan May 29, 2012 TABLE OF CONTENTS Contents STATEMENT BY SECRETARY SEBELIUS.......................................................................... iii EXECUTIVE SUMMARY ......................................................................................................... iv CHAPTER 1: INTRODUCTION................................................................................................ 1 CHAPTER 2: DETECTION AND CHARACTERIZATION OF A FUTURE INFLUENZA PANDEMIC ................................................................................................................................... 5 CHAPTER 3: COMMUNITY MITIGATION MEASURES ................................................... 8 CHAPTER 4: MEDICAL SURGE CAPACITY ..................................................................... 12 CHAPTER 5: MEDICAL COUNTERMEASURES (MCM) FOR INFLUENZA OTHER THAN VACCINES ..................................................................................................................... 17 CHAPTER 6: VACCINE MANUFACTURING, DISTRIBUTION, AND POST- DISTRIBUTION......................................................................................................................... 25 CHAPTER 7: COMMUNICATIONS....................................................................................... 17 CHAPTER 8: CROSS-CUTTING PREPAREDNESS ISSUES............................................ 33 CHAPTER 9: INTERNATIONAL PARTNERSHIPS AND CAPACITY BUILDING ACTIVITIES
    [Show full text]
  • OPTIONS X Programme
    Options X for the Control of Influenza | WELCOME MESSAGES BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION Protecting people from the ever-changing threat of influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM BREAKTHROUGH INFLUENZA VACCINES TAKE LARGE DOSES OF INNOVATION CONTENT OPTIONS X SUPPORTERS ------------------- 4 OPTIONS X EXHIBITORS & COMMITTEES ------------------- 5 AWARD INFORMATION ------------------- 6 WELCOME MESSAGES ------------------- 7 SCHEDULE AT A GLANCE ------------------- 10 CONFERENCE INFORMATION ------------------- 11 SOCIAL PROGRAMME ------------------- 14 ABOUT SINGAPORE ------------------- 15 SUNTEC FLOORPLAN ------------------- 16 SCIENTIFIC COMMUNICATIONS ------------------- 17 PROGRAMME ------------------- 19 SPEAKERS ------------------- 31 SPONSORED SYMPOSIA ------------------- 39 ORAL PRESENTATION LISTINGS ------------------- 42 POSTER PRESENTATION LISTINGS ------------------- 51 ABSTRACTS POSTER DISPLAY LISTINGS ------------------- 54 SPONSOR AND EXHIBITOR LISTINGS ------------------- 80 EXHIBITION FLOORPLAN ------------------- 83 Protecting people from the ever-changing threat of NOTE ------------------- 84 influenza takes unwavering commitment. That’s why we’re dedicated to developing advanced technologies and vaccines that can fight influenza as it evolves. We’re with you. ON THE FRONT LINETM Options X for the Control of Influenza | OPTIONS X SUPPORTERS
    [Show full text]
  • Non-Pharmaceutical Measures to Prevent Influenza Transmission
    September 2011 Non-Pharmaceutical Measures to Prevent Influenza Transmission: The Evidence for Individual Protective Measures Alexis Crabtree, MPH, 1 and Bonnie Henry,MD, MPH, FRCP(C)1,2 1University of British Columbia; 2British Columbia Centre for Disease Control Key Points Introduction • Mask use by cases and/or household contacts may be efficacious A wealth of knowledge has become in reducing the transmission of influenza, but that effectiveness available concerning influenza is likely reduced by poor compliance. Mask use in the community prevention and control in the wake of setting is of dubious benefit, as is the use of N95 respirators rather the 2009 H1N1 pandemic. The purpose than surgical masks outside of health care settings. of this review is to summarize the recent • Isolation and quarantine are effective and acceptable interventions literature on several non-pharmaceutical to reduce the spread of influenza, particularly pandemic influ- interventions: masks; quarantine, enza. Social distancing measures (excluding school closures and isolation, and social distancing; and prohibitions on mass gatherings, which are covered in another hand hygiene, respiratory hygiene, and paper in this series (Roth, 2011)), however, are of unproven value cleaning of fomites. and associated with low uptake. Special attention should be paid to providing tools and supports to those in quarantine or isolation, particularly to vulnerable groups. Masks A recently updated Cochrane review • Moderate evidence exists to support recommendations for hand concluded that mask use can interrupt and respiratory hygiene, especially in children. Further research is the transmission of influenza (1). While needed to show benefits from cleaning and disinfection of surfac- es in household and public spaces.
    [Show full text]
  • 2017 Update to the Hhs Pandemic Influenza Plan
    Pandemic Influenza Plan 2017 UPDATE U.S. Department of Health and Human Services Contents FOREWORD .............................................................................................................. 3 EXECUTIVE SUMMARY ........................................................................................... 5 INTRODUCTION ........................................................................................................ 7 SCOPE, AUDIENCE, AND PURPOSE ................................................................... 10 INFLUENZA RESPONSE ACTIVITIES ................................................................... 11 PLANNING TOOLS FOR PREPARATION AND RESPONSE ............................... 12 THE 2017 UPDATE TO THE HHS PANDEMIC INFLUENZA PLAN ..................... 13 Domain 1 – Surveillance, Epidemiology, and Laboratory Activities .................. 14 Domain 2 – Community Mitigation Measures .................................................... 18 Domain 3 – Medical Countermeasures: Diagnostic Devices, Vaccines, Therapeutics, and Respiratory Devices ............................................................. 21 Domain 4 – Health Care System Preparedness and Response Activities ....... 27 Domain 5 – Communications and Public Outreach ........................................... 30 Domain 6 – Scientific Infrastructure and Preparedness .................................... 32 Domain 7 – Domestic and International Response Policy, Incident Management, and Global Partnerships and Capacity Building ........................
    [Show full text]
  • V21 MTG 0033 List of Particip
    THE FIRST WHO INTEGRATED MEETING ON DEVELOPMENT AND CLINICAL TRIALS OF INFLUENZA VACCINES THAT INDUCE BROADLY PROTECTIVE AND LONG-LASTING IMMUNE RESPONSES Baptist University, Hong Kong 24 – 26 January 2013 LIST OF PARTICIPANTS Dr Akira Ainai, Emeritus Member, National Institute of Infectious Diseases, Tokyo, Japan Dr Christopher Ambrose, Senior Director, Medical Affairs, MedImmune, Gaithersburg, United States of America Professor Filippo Ansaldi, Health Sciences, University of Genoa and Hygiene Unit, Genoa, Italy Dr Robert L. Atmar, Associate Professor, Department of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, United States of America Dr Emma Ball, CSL Limited A.C.N., Parkville, Victoria, Australia Dr Pamuk Bilsel, FluGen Inc., Madison, United States of America Mr Albert Chan, President, Hong Kong Baptist University, Hong Kong, China Dr Paul Chan, Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China Dr Marta Coehlo Nunes, Respiratory and Meningeal Pathogens Research Unit, Wits University, Johannesburg, South Africa Dr Ben Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Dr Manon Cox, President and CEO, Protein Sciences Corporation, Meridien, United States of America Professor Rebecca Cox, Influenza Centre, The Gade Institute, University of Bergen, Bergen, 5021 Norway Dr Giuseppe Del Giudice, Global Head Translation Medicine, Novartis Vaccines and Diagnostics S.p.A, Divisione Biologici
    [Show full text]
  • Disinfecting and Sanitizing
    Volume 4, Issue 2 Disease Prevention Information for Child Care Providers December 2014 Disinfecting and Sanitizing Group care settings such as child cares, preschools, and school-age programs provide ideal conditions for spreading germs that cause illness. Caregivers use cleaning, sanitizing, and disinfecting to help reduce the Call or Email Us! number of germs in the environment. Due to some recent changes made by the bleach industry, now is a good time to review your child Main line care’s cleaning and sanitizing/disinfecting practices and make sure the 425.339.5278 products and procedures you are using are doing the job right. [email protected] What three steps are required? Public Health Nurse Alba Suárez It is important to follow all three steps in order to get rid of germs on 425.339.5228 surfaces: 1) Clean the surface with plain soap and water. [email protected] 2) Rinse the soap off the surface with plain water. Environmental Health Specialist 3) Sanitize or disinfect the surface. Micha Horn 425.339.8712 How did bleach solutions recently change? [email protected] In the past, almost all bleach that one could find on store shelves was between 5.25% and 6.0% sodium hypochlorite (the active ingredient in bleach). All the In this issue… recipes that had previously been published for child cares to make bleach Disinfecting & Sanitizing… water solutions assumed a concentration Chemical Safety…. of 5.25% to 6.0% bleach. Last year, many Bleach Chart…. bleach manufacturers started making a Disease in the News…….. “concentrated” bleach formula containing 8.25% sodium hypochlorite.
    [Show full text]
  • Research Findings from Nonpharmaceutical Intervention Studies for Pandemic Influenza And&Nbsp
    Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research Allison E. Aiello, PhD, MS,a Rebecca M. Coulborn, MPH,a Tomas J. Aragon, DrPH,b Michael G. Baker, MBChB, DPH, FAFPHM,c Barri B. Burrus, PhD,d Benjamin J. Cowling, PhD,e Alasdair Duncan, MPH,c Wayne Enanoria, PhD, MPH,b M. Patricia Fabian, ScD, MS,f,g Yu-hui Ferng, MPA,h Elaine L. Larson, PhD, RN, FAAN, CIC,h,i Gabriel M. Leung, MD, MPH, CCFP, FFPH, FHKCCM, FHKAM,e Howard Markel, MD, PhD,j Donald K. Milton, MD, DrPH,k Arnold S. Monto, MD,a Stephen S. Morse, PhD,i J. Alexander Navarro, PhD,j Sarah Y. Park, MD, FAAP,l Patricia Priest, DPhil, MBChB, MPH, FAFPHM,c Samuel Stebbins, MD, MPH,m Alexandra M. Stern, PhD,j Monica Uddin, PhD,a Scott F. Wetterhall, MD, MPH,d and Charles J. Vukotich Jr, MSm Ann Arbor, Michigan; Berkeley, California; Otago, New Zealand; Research Triangle Park, North Carolina; Hong Kong, People’s Republic of China; Lowell, Massachusetts; Boston, Massachusetts; New York, New York; College Park, Maryland; Honolulu, Hawaii; and Pittsburgh, Pennsylvania In June 2006, the Centers for Disease Control and Prevention released a request for applications to identify, improve, and evaluate the effectiveness of nonpharmaceutical interventions (NPIs)—strategies other than vaccines and antiviral medications—to mitigate the spread of pandemic influenza within communities and across international borders (RFA-CI06-010). These studies have provided major contributions to seasonal and pandemic influenza knowledge. Nonetheless, key concerns were identified related to the accept- ability and protective efficacy of NPIs.
    [Show full text]
  • Your Best Protection Against Flu
    Your Best Protection Against Flu Millions of people get the flu every year, hundreds of thousands of people are hospitalized, and thousands or tens of thousands of people die. The Centers for Disease Control and Prevention (CDC), public health professionals, and our practice recommend that everyone 6 months of age and older should get a flu vaccine every year. Flu vaccination can reduce flu illnesses, doctors’ visits, and missed work and school due to flu, as well as prevent serious flu complications that can result in hospitalization and even death.1,2 CDC estimates that during the 2016–2017 flu season, flu vaccination prevented an estimated 5.3 million flu illnesses, 2.6 million flu medical visits, and 85,000 flu hospitalizations.3 Flu Vaccine Reduces Your Risk of Flu A flu vaccine is the best way to help During recent seasons, flu vaccine has While some people who get a flu vaccine prevent flu and its potentially serious reduced the risk of flu illness in vaccinated still get sick, vaccination can make their complications. Remember that flu vaccine people by between 30% and 60%.(4,5) A 2017 illness less severe. Two studies among not only protects you, but it also can help study was the first of its kind to show that flu hospitalized flu patients showed that flu protect those around you. vaccination can significantly reduce vaccination reduced intensive care unit a child’s risk of dying from influenza. admissions and duration of hospitalization. Flu Vaccination Especially Important for Some Flu vaccination is especially important for people who are at high risk of developing serious complications from flu, including adults 65 and older, children younger than 5 years, pregnant women, and people with certain chronic health conditions, such as diabetes, heart disease, and asthma.
    [Show full text]
  • Use of Facemasks and Respirators in an Influenza Pandemic” Published in 2011
    The Use of Facemasks and Respirators during an Influenza Pandemic Scientific Evidence Base Review May 2014 Title: The Use of Facemasks and Respirators during an Influenza Pandemic: Scientific Evidence Base Review Author: PH-HPER-ID&BP 10200 Commissioned by the Department of Health and produced by Public Health England Document Purpose: A review of the scientific evidence base on the use of facemasks and respirators during an influenza pandemic Publication date: 05/2014 Target audience: Supporting Documents for UK Influenza Pandemic Preparedness Strategy Contact details: Elizabeth Paterson Richmond House 79 Whitehall LONDON SW1A 2NS Email: [email protected] You may re-use the text of this document (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit www.nationalarchives.gov.uk/doc/open-government-licence/ © Crown copyright Published to gov.uk, in PDF format only. www.gov.uk/dh May 2014 Table of contents Page Executive summary 5 Background 15 Methods 16 Results 20 Discussion 43 Conclusion and acknowledgements 51 References 53 Annexes 59 2 Document information Document date: March 2013 Final Version Document sponsor: Influenza and Respiratory Virus Delivery Board, Public Health England Authorised by: Professor John Watson Update authors and affiliations: Matthew Dixon Scientific Review Coordinator, Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control, Public Health England Nick Phin Consultant Epidemiologist, Public Health England Head of Legionella and Influenza Preparedness and Response Section Visiting Professor, Department of Health and Social Care, University of Chester Contact: [email protected] 3 Acknowledgements The original review was written by Dr Faisal Bin-Reza and Dr Mary Chamberland in 2010.
    [Show full text]